Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer
This study is planned to include 80 patients with HRD positive HER2-negative advanced breast cancer to receive fluzoparib alone or fluzoparib combined with camrelizumab to observe and evaluate the efficacy and safety of fluzoparib combined with or without camrelizumab in the treatment of HRD positive HER2-negative advanced breast cancer.
Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer
DRUG: Fluzoparib|DRUG: Fluzoparib+Camrelizumab
Objective Response Rate, Objective response is defined as a complete response (CR) or partial response (PR) according to RECIST v.1.1.recorded from randomization until disease progression or death due to any cause, Up to 3 years
Progress-free survival, Time from randomization to the first documentation of objective tumor progression or to death due to any cause, Up to 3 years|Overall Survival, Time from randomization to date of death due to any cause. according to the RECIST version 1.1 recorded in the time period between randomization and disease progression or death to any cause., Up to 3 years|QoL questionnaire （quality of life）, Up to 3 years|Adverse effect (AE), Any adverse effect occurred in the treatment, Up to 3 years
This study is planned to include 80 patients with HRD positive HER2-negative advanced breast cancer to receive fluzoparib alone or fluzoparib combined with camrelizumab to observe and evaluate the efficacy and safety of fluzoparib combined with or without camrelizumab in the treatment of HRD positive HER2-negative advanced breast cancer.